WHY INVEST IN RECARDIO

RECARDIO offers investors exposure to a de-risked, late clinical-stage cardiovascular asset in Phase 3 and 2, with trial design approved by both FDA and EMA - a critical regulatory validation milestone that substantially reduces clinical and regulatory risk.

The company is raising capital to fund patient enrollment in its clinical trial programs, and support business development activities with global pharmaceutical leaders.

 

Detailed financial information is available to qualified investors under NDA upon request.